Industry Outlook: Healthcare & Life Sciences — Week of August 24, 2026

Market Outlook

• Employer costs jump, GLP‑1s reshape revenue mix. Aon projects employer healthcare costs will rise another 9.5% in 2027, while Wells Fargo flags GLP‑1s as a structural shock to a system built around treating obesity complications. Payers and large employers will lean harder into value-based specialty care, digital programs, and prior auth controls, which raises the bar for data sharing, outcomes reporting, and integration with payer platforms.
• Retail and virtual care deepen Medicare reach. SCAN Group and Costco are expanding their cobranded Medicare products, pairing retail reach with managed care infrastructure. Combined with Cityblock Health's scale ambitions and home-based care funding for players like Happy Health, care delivery is tilting toward hybrid models that expect tight EHR connectivity, remote monitoring, and member-facing digital experiences tuned to seniors and dual-eligibles.
• Specialty and brain health services professionalize. Radial is acquiring non-clinical assets of a 20-clinic interventional psychiatry group focused on TMS and Spravato, and Included Health is partnering with Carrum Health for value-based specialty care. Specialty networks are becoming data-driven platforms that expect clean clinical data feeds, outcomes analytics, and integrated scheduling and authorization flows across EHRs and telemedicine stacks.

Discussion: Expect payer and employer buyers to push harder on demonstrable outcome improvements and total cost of care impact. Product roadmaps that do not expose clear value metrics through standards-based data exchange will lose ground in RFPs.

Headwinds

• AI governance friction hits clinical deployment pace. The AMA's new AI framework assumes physicians remain in the loop, while opinion pieces are openly questioning whether physician‑AI hybrids are optimal and whether one-size-fits-all review processes misjudge risk. Overly broad governance can under-govern high-risk generative models yet block narrow AI that actually reduces privacy exposure, slowing pilots and forcing rework of AI tooling already in flight.
• Epic AI scrutiny and FTC probe raise antitrust risk. Epic's AI strategy is described as a continuation of a long-term roadmap rather than a pivot, yet the company now faces FTC scrutiny while rolling out agentic AI across its ecosystem. Health systems that over-index on Epic-native AI could face concentration risk, reduced negotiating leverage, and future compliance constraints if regulators constrain platform bundling or data use practices.
• Cybersecurity gaps in rural care under regulatory spotlight. Analysis of rural US healthcare highlights serious cybersecurity weaknesses, with CMS funding framed as necessary to fix unseen infrastructure issues. As regulators and payers tie funding to security posture, underinvestment in identity, segmentation, and monitoring in smaller facilities becomes a direct business and reputational risk for integrated delivery networks and virtual care platforms serving rural regions.

Discussion: CTOs should assume tighter AI oversight and security expectations are coming and design for auditability now. Map AI use cases to differentiated governance tiers, and baseline cyber maturity across rural and affiliate sites before CMS or state programs dictate the agenda.

Tailwinds

• Clinician‑in‑the‑loop AI gains policy legitimacy. The AMA's AI framework, while conservative, explicitly assumes physicians stay in the loop as AI advances. That stance gives health systems and vendors a clearer path to scale decision support, documentation assistance, and workflow agents, as long as products can demonstrate clear handoffs, explainability, and traceable clinician accountability.
• FDA momentum for advanced therapies and DTx‑adjacent tools. Ultragenyx secured FDA approval for an ultra‑rare disease gene therapy, and Merck plus Moderna reported a first-in-class result for a personalized mRNA melanoma therapy. These milestones keep regulators and payers focused on long-term outcomes, real-world evidence, and risk-based monitoring, creating pull for companion digital tools, data platforms, and pharmacovigilance AI that can support complex post-market commitments.
• Home‑based and behavioral care see fresh capital. Happy Health raised 75 million dollars for home-based care, UnitedHealthcare expanded behavioral coaching to 13 million members, and Radial is scaling interventional psychiatry infrastructure. These moves strengthen demand for telemedicine platforms, remote monitoring, and AI triage that can integrate behavioral, medical, and social data with payer and provider systems.

Discussion: Use the policy and funding tailwinds to push AI and data platform initiatives that are tightly tied to clinician workflows, specialty care, and home-based models. Prioritize capabilities that produce regulatory-grade data and documentation by design.

Tech Implications

• AI governance, from pharmacovigilance to clinical ops. Industry commentary on AI in pharmacovigilance stresses that governance will determine success, not algorithms alone, and the same logic is starting to shape clinical AI. Health systems will expect model provenance tracking, data lineage, policy-as-code for AI access, and continuous performance monitoring across both safety and operational use cases.
• EHR platforms push agentic AI, startups go niche. Epic is rolling out AI agents as part of a long-planned roadmap while startups focus on specialized tools that sit on top of EHRs. Architecture decisions now need to balance native EHR AI, which offers tight integration but platform lock-in, with vendor-agnostic services that rely on FHIR, HL7, and event-driven patterns to plug into multiple clinical systems.
• Security and data quality become table stakes for value-based care. Rural cybersecurity gaps, rising payment integrity concerns, and high prior auth denial rates are pushing payers toward more automated, data-driven oversight. That shift raises expectations for clean, structured data from EHRs and telehealth platforms, stronger identity and access controls, and auditable integration flows that can support automated utilization review without creating new privacy exposure.

Discussion: Engineering teams should invest in three areas: AI governance tooling, standards-first integration with EHR and payer systems, and security architecture that can be rolled out uniformly across flagship and rural or affiliate sites. Treat explainability, observability, and identity as first-class features in new builds.

CTO Action Items

Revisit your AI portfolio and classify use cases into risk tiers, then align each tier with concrete controls for data access, human oversight, and monitoring, drawing from both the AMA framework and internal risk appetite. For EHR strategy, avoid single-vendor lock-in for AI by insisting on FHIR-based APIs, event streams, and model-agnostic orchestration layers that can work with Epic-native tools and third-party services. Use current CMS and payer attention on cybersecurity and payment integrity to secure budget for identity modernization, rural network segmentation, and centralized logging that covers home-based and affiliate providers. Finally, for any product touching specialty, behavioral, or home-based care, build in outcomes capture and prior-authorization friendly data structures so you can prove value and reduce friction with payers facing rising cost pressure.